Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biosimilar Trends Report

- PMLiVE

Amgen leukaemia drug gets FDA priority review

Adds to breakthrough status for blinatumomab

- PMLiVE

Amgen biosimilar matches AbbVie’s Humira in psoriasis trial

ABP 501 set to compete with world’s biggest-selling drug

EU flag

Biosimilars could make EU big cost savings after slow start

Report says biological copies could cut health spending in region by $11bn

- PMLiVE

Amgen files breakthrough leukaemia antibody in US

Already received top status from the FDA for the treatment of ALL

- PMLiVE

Amgen submits melanoma and cholesterol drugs to EMA

Regulator will assess talimogene laherparepvec and evolocumab

- PMLiVE

Amgen claims first-to-file spot in PCSK9 inhibitor race

Evolocumab is part of new class of treatment to tackle high cholesterol

- PMLiVE

Amgen gets priority review for chronic heart failure hope

Raises expectations for early entry onto US market for ivabradine

Elliott Levy joins Amgen from BMS

He is appointed senior VP, global development

- PMLiVE

Celltrion submits biosimilar Remicade for US approval

Drug is second to be assessed by FDA under biosimilars pathway

- PMLiVE

Amgen hit as Kyprolis fails myeloma study

Inability to improve overall survival could dent expanded use prospects

- PMLiVE

FDA ‘must publish biosimilar naming guide soon’

US politicians push regulator to finalise guidance

- PMLiVE

Amgen closes on second-line use for Kyprolis

Multiple myeloma therapy posts positive interim phase III results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links